Related Experiment Video
Updated: Mar 26, 2026
A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models
Dobromir Dimitrov1, James G Kublin2, Scott Ramsey3
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 1100 Fairview Ave. N., PO Box 19024, Seattle, WA 98109, USA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 1100 Fairview Ave. N., PO Box 19024, Seattle, WA 98109, USA; Department of Applied Mathematics, University of Washington, Seattle, WA, 1959 NE Pacific St, Box 357155, Seattle, WA 98195, USA.
Immediate rollout of a less effective HIV vaccine prevents more infections than waiting for a highly effective one. Developing correlates of protection can speed up the assessment of clade-specific vaccines.
Area of Science:
- * Immunology
- * Epidemiology
- * Mathematical Modeling
Background:
- * Candidate human immunodeficiency virus (HIV) vaccines often rely on clade-specific designs, limiting their immediate applicability.
- * Developing and testing clade-specific vaccines is time-consuming, delaying potential interventions.
- * HIV-1 envelope immune responses are crucial for vaccine-induced protection.
Purpose of the Study:
- * To mathematically model and compare the effectiveness of immediate vs. delayed HIV vaccination strategies.
- * To evaluate the impact of vaccine efficacy and specificity on preventing new HIV infections.
- * To assess the benefits of using non-clade matched vaccines with reduced efficacy versus delayed clade-specific vaccines.
Main Methods:
- * Simulation of the HIV epidemic in San Francisco and South Africa using a mathematical model.
- * Projection of three vaccination strategies: immediate low-efficacy non-matched, delayed high-efficacy clade-specific, and a hybrid approach.
- * Analysis of infection prevention over a 30-year period under different vaccine scenarios.
Main Results:
- * Immediate vaccination with a 20-40% efficacy non-clade matched vaccine prevented thousands (SF) to millions (SA) of new infections over 30 years.
- * A delayed 50% efficacy clade-specific vaccine took 6-12 years to break even with lower efficacy immediate vaccines in South Africa.
- * Replacing a lower efficacy vaccine with a higher efficacy one improved outcomes but immediate lower efficacy vaccination showed significant impact.
- * Higher vaccine efficacy is crucial for substantial long-term impact.
Conclusions:
- * Immediate deployment of even reduced-efficacy, non-clade matched HIV vaccines is epidemiologically advantageous in the short term.
- * Developing correlates of protection is essential for faster assessment and deployment of clade-specific vaccines.
- * A balance between immediate availability and achieving higher efficacy is necessary for optimal long-term HIV prevention. *
